Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

31.83

+0.01 (0.03%)

as of Jul 15, 2026, 3:23:30 pm Market Open.

69 watching

Investor Insights

Jul 15, 2026, 12:00 am

This summary was created by AI, based on 3 opinions in the last 12 months.

Teva Pharmaceutical (TEVA-N) is experiencing a significant turnaround under its current CEO, with a remarkable 264% increase since January 2023. The demand for GLP (glucagon-like peptides) remains strong; however, the entry of more generics into the market could lead to declining prices. While analysts highlight the potential for innovation, concerns remain about Teva's lack of innovative capabilities. The stock has shown strong momentum, breaking out over $21 in September and maintaining positive accumulation trends for the past six months. Despite not offering dividends, analysts have set a price target of $34.50 for the stock, indicating further potential growth amidst favorable market conditions for drug stocks.

Consensus

Bullish

Valuation

Undervalued

Similar

Pfizer,PFE

PAST TOP PICK

(Was a top pick on Jan 25/01 up 11%) Still likes, but may be fully valued now.

PAST TOP PICK

(Was a top pick on Aug 3/00 up 1.3%) Still likes and still buying.

BUY

Likes the generic drug sector as patent expirations are coming. Global. Good cash flow

TOP PICK

World's largest generic drug company. Good distribution. Patents are going off now so generics are prospering.

BUY

Likes the generic drug space. Govts will be pressured for lower health costs. Prefers this over Biovale

Showing 271 to 275 of 275 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Dan Rohinton

iA Global Asset Management

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)